Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's
disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild …

Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …

Background Alzheimer's disease and its complications are the leading cause of death in
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …

Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …

Summary Background Diagnosis of Alzheimer's disease in Down syndrome is challenging
because of the absence of validated diagnostic biomarkers. We investigated the diagnostic …

Objective To determine the cutoffs that optimized the agreement between 18F‐Florbetapir
positron emission tomography (PET) and Aβ1‐42, Aβ1‐40, tTau, pTau and their ratios …

Epidemiological and experimental studies suggest that a disease-aggravating
neuroinflammatory process is present at preclinical stages of Alzheimer's disease. Given …

Individuals with Down syndrome (DS) have an increased risk for epilepsy during the whole
lifespan, but especially after age 40 years. The increase in the number of individuals with DS …

BACKGROUND: Recent advances in medical care have increased life expectancy and
improved the quality of life for people with Down syndrome (DS). These advances are the …

Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of
progression of several neurodegenerative diseases. Among them, CSF neurofilament light …